The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies

NCT04097769 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: HX009

Sponsor

Waterstone Hanxbio Pty Ltd